A clinical case of successful management of a patient with Duchenne muscular dystrophy caused by a nonsense mutation in the DMD gene

Duchenne muscular dystrophy (DMD) is a hereditary progressive muscular dystrophy with an X-linked recessive type of inheritance, mainly manifested in boys, characterized by an onset at an early age, rapidly progressive atrophy of the striated muscles of the limbs, trunk, and  damage of cardiac muscle. This process leads to a gradual loss of motor skills, cardiovascular and respiratory complications, deterioration of the musculoskeletal system, which, ultimately, significantly worsens the patient’s quality of life and reduces its duration. Currently, there are new drugs for the pathogenetic therapy of DMD. Their effectiveness is maximum with early initiation of therapy in the outpatient stage of the disease. Therefore, the age of diagnosis and the ability to suspect pathology in its early stages has become especially relevant in recent years.
One of the new treatments for DMD is ataluren therapy. This therapy refers to pathogenetic and similar affects a number of patients with a nonsense mutation in the DMD gene. The combination of ataluren and glucocorticosteroids can increase the duration of the outpatient period and stabilize the state of respiratory and cardiac functions. The article presents a clinical example of a three-year follow-up of a patient suffering from DMD due to a nonsense mutation in the DMD gene, receiving combination therapy with glucocorticosteroids and ataluren.

Contributions:
Podkletnova T.V. — concept, text writing, text editing;
Uvakina E.V. — concept, text writing, text editing;
Popovich S.G. — concept, text writing, text editing;
Lyalina A.A. — concept, text writing, text editing;
Kuzenkova L.M. — сoncept; text editing.
All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: April 14, 2021
Accepted:  May 12, 2022
Published: June 30, 2022

1. Fornander F., Solheim T.Å., Eisum A.V., Poulsen N.S., Andersen A.G., Dahlqvist J.R., et al. Quantitative muscle MRI and clinical findings in women with pathogenic dystrophin gene variants. Front. Neurol. 2021; 12: 707837. https://doi.org/10.3389/fneur.2021.707837

2. Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9(1): 77-93. https://doi.org/10.1016/s1474-4422(09)70271-6

3. Birnkrant D.J., Bushby K., Bann C.M., Apkon S.D., Blackwell A., Brumbaugh D., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018; 17(3): 251-67. https://doi.org/10.1016/s1474-4422(18)30024-3

4. Emery A.E.H., Muntoni F., Quinlivan R. Duchenne Muscular Dystrophy. Oxford, UK: Oxford University Press; 2015.

5. Lisak R.P., Truong D.D., Carroll W., Bhidayasiri R., eds.International Neurology. John Wiley & Sons; 2011.

6. Bello L., Gordish-Dressman H., Morgenroth L.P., Henricson E.K., Duong T., Hoffman E.P., et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015; 85(12): 1048-55. https://doi.org/10.1212/wnl.0000000000001950

7. Cowen L., Mancini M., Martin A., Lucas A., Donovan J.M. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry. BMC Neurol. 2019; 19(1): 84. https://doi.org/10.1186/s12883-019-1304-8

8. Ward L.M., Kinnett K., Bonewald L. Proceedings of a parent project muscular dystrophy bone health workshop: morbidity due to osteoporosis in DMD: the Path forward may 12-13, 2016, Bethesda, Maryland, USA. Neuromuscul Disord. 2018; 28(1): 64-76. https://doi.org/10.1016/j.nmd.2017.05.012

9. Bushby K., Finkel R., Wong B., Barohn R., Campbell C., Comi G.P., et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014; 50(4): 477-87. https://doi.org/10.1002/mus.24332

10. Mercuri E., Muntoni F., Osorio A.N., Tulinius M., Buccella F., Morgenroth L.P., et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J.Comp. Eff. Res. 2020; 9(5): 341-60. https://doi.org/10.2217/cer-2019-0171

11. NICE. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. Highly specialised technologies guidance; 2016. Available at: https://www.nice.org.uk/guidance/hst3

12. Aslesh T., Maruyama R., Yokota T. Skipping multiple exons to treat DMD-promises and challenges. Biomedicines. 2018; 6(1): 1. https://doi.org/10.3390/biomedicines6010001

13. Frank D.E., Schnell F.J., Akana C., El-Husayni S.H., Desjardins C.A., Morgan J., et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020; 94(21): e2270-82. https://doi.org/10.1212/wnl.0000000000009233

14. Chamberlain J.R., Chamberlain J.S. Progress toward gene therapy for Duchenne muscular dystrophy. Mol. Ther. 2017; 25(5): 1125-31. https://doi.org/10.1016/j.ymthe.2017.02.019

15. Romero N.B., Braun S., Benveniste O., Leturcq F., Hogrel J.Y., Morris G.E., et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum. Gene Ther. 2004; 15(11): 1065-76. https://doi.org/10.1089/hum.2004.15.1065